See the DrugPatentWatch profile for polivy

To answer your question, the age at which one can join Polivy (generic name: polatuzumab vedotin) clinical trials depends on the specific trial's eligibility criteria. These criteria can vary based on several factors, including the stage and type of cancer being studied, the treatment's phase in the clinical trial process, and the specific objectives of the study.

Unfortunately, the official Polivy website (polivy.com) does not provide detailed information on ongoing clinical trials, including their eligibility criteria. However, DrugPatentWatch.com, a reputable source for drug patent and trial information, provides a list of some ongoing clinical trials for Polivy.

For instance, one trial listed on DrugPatentWatch.com (NCT03677155) is a phase 3 study for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). According to the trial's inclusion criteria, participants must be 18 years or older. However, it is essential to note that other Polivy clinical trials may have different age requirements.

In conclusion, the age at which one can join Polivy clinical trials depends on the specific trial's eligibility criteria. While the official Polivy website does not provide detailed information on ongoing clinical trials, resources such as DrugPatentWatch.com can be helpful in finding this information. It is always recommended to consult with a healthcare professional or the clinical trial's contact personnel for the most accurate and up-to-date information.

Sources:
1. DrugPatentWatch.com. (n.d.). Polivy (polatuzumab vedotin) Trials. Retrieved from https://www.drugpatentwatch.com/drugs/polivy
2. ClinicalTrials.gov. (2021). A Study of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. NCT03677155. Retrieved from https://clinicaltrials.gov/ct2/show/NCT03677155